UltraGreen.ai, a Singapore-based player in fluorescence-guided surgical technologies and precision healthcare solutions, has announced the signing of a $188 million strategic investment led by 65 Equity Partners (65EP) and Vitruvian Partners (“Vitruvian”), with participation from August Global Partners. The investment reflects strong confidence in UltraGreen’s AI-powered surgical imaging platform and will support the Company’s next phase of growth.
UltraGreen, through its Diagnostic Green business, leads the Fluorescence Guided Surgery (FGS) market as the world’s largest provider of Indocyanine Green (ICG), marketed as IC-Green in the US and Verdye internationally. ICG is used in more than 90% of FGS procedures globally.
Ravi Sajwan, Founder and CEO of UltraGreen.ai, said, “We are delighted to welcome 65EP, Vitruvian and August as shareholders of UltraGreen.ai. This investment marks their confidence in our mission to democratise precision surgery worldwide and enables us to leverage their deep strategic expertise in scaling healthcare technologies across global markets. Their backing validates our vision of making data-driven surgical intelligence the standard of care in operating rooms worldwide. We believe the investment also aligns seamlessly with our strategic expansion and diversification, particularly in Asia.”
The partnership with 65EP, Vitruvian and August strengthens UltraGreen’s ability to expand its fluorescence ecosystem, integrating ICG agents, advanced imaging hardware and proprietary AI quantification software. These technologies are increasingly applied in high-value procedures, including colorectal, minimally invasive and robotic surgery, where they help surgeons assess perfusion and visualise anatomy with greater precision. By spanning the full surgical workflow –from visualisation to quantification to decision support – UltraGreen helps deliver improved outcomes for both surgeons and patients.
